Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I think RG anticipates a higher share price.

If we acquire say 20% or 40% of a company ......what we spend is an expenditure on the books...if we own any of the assets that % goes into our asset base....the yearly/quarterly revs less cost at our % ownership then goes to our bottomline in that quarter...the cost of acquisition would normally be a one time expense and in most cases be excluded in future EPS prognostications...of course in our case...our own rev's should excluded because of being one time payments(as far as we know that is)...so we're sort of different animal when you read EPS numbers and PE etc etc.

Share
New Message
Please login to post a reply